Affymax initiates enrollment in Phase II study of anemia drug
The trial is intended to generate data for Hematide as an anemia correction therapy in this segment of the chronic renal failure patient population, some of whom may
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Invitrogen scientists will support research programs at the Pharmacogenomics Centre to improve the efficiency and speed with which researchers can identify single nucleotide polymorphisms (SNPs), differences in single